So, downregulation of TGFB2 results in the expression of anti-apoptotic proteins BCL2 and BCL-W, and enhanced cancer cell survival, which confers platinum resistance in NSCLC and 5-FU resistance in CRC cells, respectively [57,58]. The gene discussed is TGFB2; the disease is cancer.